Clinical Trial Update: The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and efficacy of canakinumab in patients aged 4 years or older with Cryopyrin-associated periodic syndrome (CAPS) in Canada h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cryopyrin-associated Periodic Syndrome

Drugs mentioned

• ILARIS (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cryopyrin Associated Periodic Syndrome | Phase 3 | Status: COMPLETED